Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added a new press release about Tozorakimab meeting primary endpoints in COPD Phase III trials (27 March 2026); removed the January 30, 2026 CSPC collaboration press release from the list.
    Difference
    0.9%
    Check dated 2026-03-28T03:42:31.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A new press release item dated 16 March 2026 about Imfinzi being approved in the EU was added. A January 29, 2026 investment announcement in China was removed.
    Difference
    0.9%
    Check dated 2026-03-21T01:06:06.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Added a press release dated 09 March 2026 about Enhertu Priority Review for HER2-positive early breast cancer; removed the 20 January 2026 press release about completing a direct NYSE listing.
    Difference
    0.9%
    Check dated 2026-03-13T20:56:24.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    Added Feb 20, 2026 press release: Calquence plus venetoclax approved in the US for first-line chronic lymphocytic leukaemia. Removed Jan 8, 2026 press release announcing Joris Silon as Head of Investor Relations.
    Difference
    0.9%
    Check dated 2026-02-20T15:25:18.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added two new press releases: Breztri Phase III KALOS/LOGOS results in The Lancet Respiratory Medicine (13 February 2026) and Full Year and Q4 2025 results (10 February 2026). Removed two older releases: Saphnelo self-administration TULIP-SC trial results (06 January 2026) and Enhertu Breakthrough Therapy Designation (22 December 2025).
    Difference
    5%
    Check dated 2026-02-13T12:37:43.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    New press releases have been added, including Datroway Priority Review, Saphnelo subcutaneous update, Imfinzi EU CHMP, NYSE listing, CSPC collaboration, and a $15B China investment. Older releases such as LATIFY trial update, Saphnelo EU subcutaneous pen approval, Enhertu/pertuzumab US first-line, ASH presence, and Baxdrostat FDA Priority Review have been removed.
    Difference
    5%
    Check dated 2026-02-05T23:56:23.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.